ArticleBMC microbiology2025
Strain-specific qPCR assay to track the vaginal colonization of the probiotic Lacticaseibacillus rhamnosus TOM 22.8 strain orally administered.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past decade, research on the female reproductive tract microbiota has grown significantly and the use of probiotics has gained growing interest in restoring vaginal microbial balance. In this context, probiotic lactobacilli, topically or orally administered, emerged as a valuable alternative or a complementary approach to conventional antimicrobial therapies. Although topical application allows for a fast and direct action on the altered vaginal ecosystem, the oral intake provides long-term benefits due to the passage through the gastrointestinal tract.
methodsIn the present study, in silico analyses were conducted to design a specific primer pair, which was validated by qPCR analysis and used to detect the orally administered Lacticaseibacillus rhamnosus TOM 22.8 probiotic strain in vaginal swabs of women with vaginal dysbiosis.
resultsData showed that qPCR confirmed the specificity of the strain-specific primer pair designed, and no amplification results were seen from 30 Lacticaseibacillus rhamnosus, Lacticaseibacillus casei, and Lacticaseibacillus paracasei strains used for comparison. In addition, the qPCR methodology allowed the detection of the Lacticaseibacillus rhamnosus TOM 22.8 probiotic strain in vaginal swab samples, with cell densities ranging from 5.24 log CFU/mL to 6.65 log CFU/mL.
conclusionThe approach used in the present study revealed the ability of the Lacticaseibacillus rhamnosus TOM 22.8 probiotic strain to survive during the GI tract passage and translocate into the vaginal ecosystem.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.